CryoLife, Inc. (NYSE:CRY) released its quarterly earnings results on Monday. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02, Bloomberg Earnings reports. The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a net margin of 5.73% and a return on equity of 7.77%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 EPS. CryoLife updated its FY17 guidance to $40-0.43 EPS.

Shares of CryoLife (CRY) traded up 2.87% during mid-day trading on Monday, reaching $19.70. The company’s stock had a trading volume of 155,616 shares. The firm’s 50 day moving average price is $19.29 and its 200-day moving average price is $17.96. The company has a market capitalization of $655.22 million, a price-to-earnings ratio of 63.96 and a beta of 0.99. CryoLife has a 1-year low of $12.99 and a 1-year high of $20.30.

Several research firms have recently commented on CRY. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research report on Monday. Northland Securities reissued a “buy” rating and issued a $23.50 target price on shares of CryoLife in a research report on Friday, April 28th. Finally, Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Thursday, June 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. CryoLife presently has a consensus rating of “Buy” and a consensus price target of $20.80.

COPYRIGHT VIOLATION NOTICE: “CryoLife, Inc. (NYSE:CRY) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at

In other CryoLife news, VP Amy Horton sold 9,577 shares of the stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $20.00, for a total transaction of $191,540.00. Following the transaction, the vice president now owns 112,282 shares of the company’s stock, valued at $2,245,640. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 6.00% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.